Jump to Navigation

FDA Investigating Deaths Following Injections of Zyprexa

The FDA announced this week that it is investigating the deaths of two patients who died several days after receiving intramuscular injections of the long-acting antipsychotic drug Zyprexa Relprevv (olanzapine pamoate). According to the investigation, both patients received appropriate doses of the drug, and both were found to have "very high olanzapine blood levels after death." High doses of olanzapine can cause delirium, cardiopulmonary arrest, cardiac arrhythmias, and impaired levels of consciousness ranging from sedation to coma. The FDA has not yet determined if the drug is the cause of the fatalities. Zyprexa Relprevv is used for treating patients with schizophrenia.

How Can I Help You?

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close
Subscribe To This Blog's Feed